French biotech Eligo Bioscience is combining two hot disciplines: #microbiome research and #gene editing, performing in vivo microbial editing for various indications. Their initial focus is on moderate-to-severe acne, but CEO Xavier Duportet sees a broad range of applications in the future. #innovation #biotechnology #research Citeline Commercial
David Wild’s Post
More Relevant Posts
-
Check out the BioBytes (an In Vivo blog) quarterly AI-related biopharma deal summary for a snapshot of the fundraising, partnership and M&A landscape. In Q2, AI-related biopharma deals were dominated by Xaira Therapeutics's $1bn venture inancing, but the quarter was also notable for sizeable public offerings by Alumis and Recursion in the US and XtalPi Inc. in Hong Kong, as well as a $142m seed round for EvolutionaryScale. Citeline Commercial
BioBytes: AI-Related Deals In Q2 2024
invivo.citeline.com
-
#Poland is slowly expanding beyond its position as a central European #generics and #biosimilars hub. More established companies like Celon Pharma S.A. are adding innovative medicine pipelines and a small number of biotechs are making international deals. Meanwhile, organizations like BioInMed are fostering the connections to build a functioning biotech innovation ecosystem. PolTREG S.A. Piotr Trzonkowski Ryvu Therapeutics Molecure Selvita Polpharma Beata Szparaga-Waśniewska, CFA Marta Winiarska
Poland’s Quiet Pivot From Generics To Innovative Treatments
invivo.citeline.com
-
#Parkinson's disease patients with the #GBA1 gene variant stand to benefit from the race to develop a treatment for the 15% of PD patients with this genetic cause. Gain Therapeutics is developing, a disease-modifying small molecule treatment that has done well in early Phase I data and it will be entering Phase Ib research this year. But big pharma and other biotechs are chasing the same indication, using a range of modalities, including gene therapy. Who will be first? Citeline Commercial
Gain Therapeutics Navigates Market Fluctuations While Developing Parkinson’s Treatment
invivo.citeline.com
-
In Vivo 2024 Rising Leader Somer Baburek, MBA is on a mission to revolutionize the diagnosis and management of #endometriosis. Dive into her remarkable journey from rodeo racer to founder of Hera Biotech. #womenshealth #leadership
Once Destined For Pro Rodeo, Women’s Health CEO Rides A Different Horse
invivo.citeline.com
-
I will be checking out a few talks and doing interviews at #CollisionConf next week here in Toronto. If you are attending, please be in touch!
-
Quris AI has developed a platform capable of simulating genetically diverse clinical trials on a chip. This innovative technology has the potential to significantly decrease the reliance of biopharma companies on animal testing and mitigate the risks associated with human trials. #AI #Biopharma #Innovation
Will AI Obviate The Need For Animal Trials?
invivo.citeline.com
-
Some highlights from the first day of #BIO2024, as contributed by Mandy Jackson, Kevin Grogan, Sarah Karlin-Smith and myself. Today is set to be a busy and exciting day! Insights from the first day include interviews on Alzheimer’s investments, dealmaking for mid-sized companies and reflections on the virtues of lean thinking.
BIO Notebook: Dealing With Rejection, Worrying About March-In Rights, And More
scrip.citeline.com
Your Go-To Life Sciences business analyst | Collating and analysing data on the latest all-things-bio trends | Extrapolating insights is my daily brain-food | Web3 'observer'⚡
3wLove seeing Eligo growing since 2015... Best is yet to come